Pregnancy ANtihypertensive Drugs: which Agent is best?
The aim of this study is to evaluate the effect of different antihypertensive drugs in women with pregnancy hypertension on maternal and fetal/neonatal outcomes.
ABOUT THE STUDY
The primary objective is to evaluate if treatment with nifedipine (calcium channel blocker), compared to labetalol (mixed alpha/beta blocker) in women with pregnancy hypertension, reduces severe maternal hypertension without increasing fetal or neonate adverse events.
WHO CAN PARTICIPATE IN THIS STUDY?
11+0 – 34+6 weeks
Diagnosis of pregnancy hypertension (Chronic/gestational or Pre-eclampsia)
>18 years old
Clinicians’ decision to initiate antihypertensive drugs
Contraindication to either Labetalol or Nifedipine
Already taking both medications.
What to expect
- You will be randomly assigned to receive one of two drugs Nifedipine or Labetalol. Both of these medications for blood pressure are usual clinical practice.
- Observational: Data input only (for the women who are eligible but excluded due to contraindication to either medication or women already taking both antihypertensive drugs)
- Post randomisation contact – safety check after 2 weeks
- Post randomisation contact – after 6 weeks (4 weekly thereafter)
For further information, please read our study leaflet.
HOW CAN I GET INVOLVED?
Giant Panda Research Team
Nuffield Department of Women’s and Reproductive Health, University of Oxford
The Women’s Centre, John Radcliffe Hospital
Phone: 01865 221107/07925148248
This study has been ethically approved by the London - South East Research Ethics Committee.
REC number: 20/LO/1110